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Homozygous familial hypercholesterolemia (HoFH) is a rare and life-threatening disease originally characterized clinically by plasma cholesterol levels >13 mmol/L (>500 mg/dL), extensive xanthomas, and marked premature and progressive atherosclerotic cardiovascular disease (ASCVD). Studies in these patients showed a severe defect in the ability to bind and internalize lowdensity lipoprotein (LDL) particles, caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR). 1 Recent genetic insights indicate that mutations in alleles of other genes, including APOB, proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDLRAP1, may be present in some individuals with HoFH. 2, 3 Many treatment guidelines emphasize that the primary goals of management are prevention of ASCVD by early and comprehensive control of hypercholesterolemia, and early detection and treatment of atherosclerotic lesions. 4 Unfortunately, HoFH is typically diagnosed when considerable coronary atherosclerosis has already developed, emphasizing the need for optimization of treatment in childhood. [2] [3] [4] In accordance with recently published guidelines, LDLcholesterol (LDL-C) targets in HoFH are <2.5 mmol/L (<100 mg/dL) (<3.5 mmol/L (<135 mg/dL) in children) or <1.8 mmol/L (<70 mg/dL) in adults with clinical ASCVD. Recommended targets are difficult to achieve in the majority of familial hypercholesterolemia patients with currently available treatments, so that the maximal LDL-C reduction that can be tolerated with therapy or to achieve at least a 50% reduction in LDL-C level is the pragmatic strategy. 2, 5 Statins have proven efficacy as the mainstay of treatment in HoFH, and have been shown to reduce cardiovascular and all-cause mortality. However, only modest reductions in LDL-C plasma levels, of 10-25%, are observed with statin therapy in most patients. Addition of the cholesterol absorption inhibitor ezetimibe further lowers LDL-C levels by 10-15%, thus providing 30-40% reduction in LDL-C levels. Combinations of statins with other cholesterollowering medications, including bile acid sequestrants, niacin, fibrates and probucol, have been used successfully in HoFH and can be considered to further lower LDL-C levels, although their use may be limited by tolerability and availability. PCSK9 inhibitors can be prescribed with efficacy, tolerability, by comparison with mipomersen and lomitapide, and lipoprotein apheresis. PCSK9 inhibitors have great potential to control LDL-C concentrations in people with severe familial hypercholesterolemia. 2, 5 Lomitapide is an oral inhibitor of the microsomal triglyceride transport protein (MTP), which is responsible for transferring triglycerides and phospholipids onto chylomicron and very low density lipoprotein during their assembly in the intestine and the liver, respectively. 5, 6 Inhibiting MTP leads to reduced secretion of these lipoproteins into the circulation. In an open-label trial in HoFH patients, lomitapide at maximally tolerated doses, in addition to the standard of care including LDL apheresis, reduced plasma LDL-C and apolipoprotein B (apoB) levels by 50% and lipoprotein(a) (Lp(a)) by 15% at 26 weeks. The most frequently observed adverse events were gastrointestinal symptoms and liver fat accumulation. Gastrointestinal adverse events were reduced by a gradual dose-escalation regimen combined with adherence to a low-fat diet and dosing outside of mealtimes. Elevations in alanine aminotransaminase >3Â upper limit of normal (ULN) were reported for 10 patients (34%). 6 Kolovou et al. showed the efficacy of lomitapide in 12 patients with HoFH. Daily lomitapide treatment with or without bi-weekly lipoprotein apheresis for 3-24 months decreased the median LDL-C level from 900 mg/dL (348-1070) at baseline to 383.5 mg/dL (214-866) after treatment and 288 mg/dL (183.7-716.6) of time-averaged level. The addition of lomitapide lowered LDL-C levels further by 56.8% compared with lipid-lowering drugs alone (p ¼ 0.005) and 54% compared with lipid-lowering drugs plus lipoprotein apheresis (p ¼ 0.031). There was no alteration in the degree of fatty liver disease during the follow-up period, which was relatively short to detect alterations in long-standing steatosis. Two patients presented with stabilization of the progressed coronary plaques evaluated by coronary computed tomography angiography. During follow-up, a side effect of transient diarrhea was reported in two patients and one patient showed elevated liver transaminase, >5 Â ULN, and had to decrease the dose of lomitapide. 7 The wide range of calculated LDL-C concentrations and no analysis of the effect of lomitapide on apoB and Lp(a) are the limitations of this study, as the authors described. This study showed the importance of the role of lomitapide in patients with HoFH with or without lipid apheresis.
Several studies showed effective LDL-C lowering by 40-50% and achievement of LDL-C targets with lomitapide. D'Erasmo et al. showed that the addition of lomitapide to usual clinical care of 15 HoFH patients (10 with mutations in the LDLR gene and five in the LDLRAP1 gene) lowered LDL-C levels by 68.2 AE 24.8% for 32.3 AE 29.7 months. During followup, 53.3% of patients reported at least one episode of diarrhea, but none was referred as severe; none had liver transaminase >5 Â ULN or had to stop treatment due to side effects. 8 Cuchel et al. reported the results of single-arm, open-label, phase 3 study of lomitapide for treatment of 29 patients with HoFH. LDL-C level was reduced by 50% from baseline (mean 8.7 mmol/L to week 26 (4.3 mmol/L; p < 0.0001) with lomitapide from 5 mg to a maximum of 60 mg a day. Four patients had aminotransaminase levels of >5 Â ULN, which resolved after dose reduction or temporary interruption of lomitapide. No patient permanently discontinued treatment because of liver abnormalities. 8 Roeters van Lennep et al. reported clinically meaningful reductions in LDL-C levels by 35-73% through lomitapide treatment in patients with HoFH. 9 Lomitapide can be used in HoFH patients who are refractory to statins, ezetimibe and PCKS9 treatment (e.g. individuals who are homozygous because of null LDLR mutations). Use of lomitapide is limited by its side-effects and very high costs. 2, 5, 10 It may be necessary and helpful for the treatment of HoFH to investigate combined treatment with lomitapide and PCSK9 inhibitors on the basis of usual care in the future.
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